Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Shi, Liangrong; Zhou, Qi; Wu, Jun; Ji, Mei; Li, Guojun; Jiang, Jingting; Wu, Changping

doi:10.1007/s00262-012-1289-2

Cited by 105 publications

(72 citation statements)

References 32 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those studies suggested that several courses of CIK treatment would be required to achieve a stable effect (47,48). The present findings indicate that CIK cell therapy aids to improve the immune status of cancer patients following several courses.…”

Section: Discussionmentioning

confidence: 62%

“…In the present study, the average percentage of CD3 + CD4 + , CD3 + and NKT cells, as well as the levels of IFN-γ following several treatment courses, were significantly higher than the values observed prior to CIK treatment in the CIK and Che-Sur groups. Shi et al (47) observed that the percentage of CD3 + and CD4 + cells, and the ratio of CD4 + /CD8 + cells were significantly higher following the first course of CIK therapy, compared with the values prior to treatment. However, in the present study, the percentages of CD3 + and CD3 + CD4 + cells were observed to be significantly higher following several courses of CIK therapy, which may be due to the difference in the detection time point (1 month in the current study vs. 2 weeks in the study by Shi et al subsequent to each course).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cytokine-induced killer (CIK) cells have been used as adoptive immunotherapy in cancer. The present study evaluated the effect of CIK cells on immune function in patients with lung cancer. Patients were divided into three groups, according to the treatment received prior to CIK cell treatment: CIK group (no prior treatment), Che-Sur group (prior chemotherapy and surgery) and Che-Rad group (prior chemotherapy and radiotherapy). Following treatment, the average percentage of cluster of differentiation (CD)3 + CD4 + , CD3 + , natural killer (NK) and NKT cells in peripheral blood was significantly higher than that prior to CIK treatment in the Che-Sur and CIK groups, and the levels of interferon-γ in serum were significantly higher than those prior to CIK treatment in the Che-Sur and CIK groups. On the contrary, the levels of interleukin-10 had decreased in these groups following CIK treatment. Subsequently, patients were divided into three groups according to the percentage of CD3 + CD56 + CIK cells that were administered to the patients. The number of NK and NKT cells increased with increasing number of CD3 + CD56 + cells. The patients in the CIK and Che-Sur groups were the most benefited ones following CIK treatment, contrarily to those in the Che-Rad group, since the increase in the number of CD3 + CD56 + CIK cells in the aforementioned patients enhanced the number of NK cells, which exhibit antitumor activity.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Among patients with all histologic subtypes of gastric cancer, immunotherapy was associated with borderline improved median OS (48.1 vs. 42.1 months, P=0.071), and significantly increased median DFS (40.4 vs. 34.1 months, P=0.044). Retrospectively stratifying patients by histologic subtype showed that patients with diffuse or mixed-type histology do not benefit from CIK therapy, however patients with intestinal-type tumors treated with CIK therapy have an improved 5-year OS (46.8% vs. 31.4%, P=0.045) and improved 5-year DFS (42.4% vs. 15.7%, P=0.023) (35).…”

Section: Adoptive Cell Transfer Therapies In Gej Cancermentioning

confidence: 99%

Immunotherapy in gastrointestinal cancers

Grierson¹,

Lim²,

Amin³

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers such as gastric, esophageal, pancreas, hepatobiliary, colorectal and anal cancers are a major cause of cancer related mortality worldwide. Traditional treatment options such as chemotherapy, surgery, radiation therapy, monoclonal antibodies and anti-angiogenic agents have been the backbone of treatment of GI cancers in various stages. Current cancer research is moving forward to incorporate immunotherapies in the treatment of GI cancers either as single agent or in combination with current available treatment modalities. This review summarizes the existing and ongoing immunotherapies in the treatment of GI cancers.

show abstract

“…A sub-population of the T-lymphocytes, differentiated in vitro by addition of specific cytokines to the media culture is the cytokine-induced killer (CIK) cells. The CIK cells are major histocompatibility complex (MHC)-unrestricted with the characteristic CD3 + CD56 + phenotype and they have been shown, in vitro and in medical practice, to be efficient killers of tumor cells (9,(17)(18)(19). These CIK cells with the ability to attack tumor cells are expressed on the cell surface of CD3/CD56.…”

Section: Cytokine-induced Killer Cells Co-cultured With Complete Tumomentioning

confidence: 99%

Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells

et al. 2013

View full text Add to dashboard Cite

Abstract. Retinoblastoma (RB) is a challenging disease that affects mostly young children. Chemical therapy has been shown to have limitations during clinical practice, principally because of the ability of RB to become resistant to the treatment. Nevertheless, chemotherapy is still the main treatment for RB, and immunotherapy has become a promising treatment for most solid tumors with fewer side effects than traditional therapies. In this study, we explored the antitumor effects of cytokine-induced killer (CIK) cells co-cultured with dendritic cells (DCs) pulsed with complete tumor antigens (DC-Ag). Cytotoxicity and specificity were evaluated on an RB cell line (RB-Y79), on a human normal retina cell line (hTERT-RPE1) and a carboplatin-resistant RB cell line. Our results showed that CIK differentiation and cytotoxicity were enhanced by co-culturing CIKs with DC-Ag. Moreover, the co-culture improved the CIK proliferation rate by increasing IL-6 and decreasing IL-10 levels in the culture medium. Furthermore, the use of DC-Ag-CIK cells had little effect on normal retinal cells but high cytotoxicity on RB cells even on carboplatinresistant retinoblastoma cells. This is the first study showing that DC cells pulsed with the complete tumor antigen improve proliferation, differentiation and cytotoxic activity of CIKs specific not only for RB but also for the chemotherapy-resistant form of the malady. Thus highly efficient immunotherapy based on DC-Ag-CIK cells may be a potential effective and safe mean of treating RB especially to patients where traditional chemical therapy has failed.

show abstract

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Cited by 105 publications

References 32 publications

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Immunotherapy in gastrointestinal cancers

Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells

Contact Info

Product

Resources

About